Decreasing Clostridium difficile Infections by an Antimicrobial Stewardship Program That Reduces Moxifloxacin Use
Open Access
- 1 September 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (9) , 5079-5083
Abstract
Clostridium difficile infections (CDI) in hospitalized patients are known to be closely related to antibiotic exposure. Although several substances can cause CDI, the risk differs between individual agents. In Vienna and other eastern parts of Austria, CDI ribotype 027 is currently highly prevalent. This ribotype has the characteristic of intrinsic moxifloxacin resistance. Therefore, we hypothesized that moxifloxacin restriction can decrease the number of CDI cases in hospitalized patients. Our antibiotic stewardship (ABS) group applied an information campaign on CDI and formal restriction of moxifloxacin in Wilhelminenspital (Vienna, Austria), a 1,000- bed tertiary care hospital. The preintervention period (period 1) was January through May 2013, and the intervention period (period 2) was June through December 2013. We recorded the defined daily doses (DDD) of moxifloxacin and the number of CDI patients/month. Moxifloxacin use was reduced from a mean (± standard error of the mean [SEM]) of 1,038 ± 109 DDD per month (period 1) to 42 ± 10 DDD per month (period 2) ( P = 0.0045). Total antibiotic use was not affected. The mean (±SEM) numbers of CDI cases in period 1 were 59 ± 3 per month and in period 2 were 32 ± 3 per month (46% reduction; P = 0.0044). Reducing moxifloxacin use in combination with providing structured information on CDI was associated with an immediate decrease in CDI rates in this large community teaching hospital.Keywords
This publication has 30 references indexed in Scilit:
- Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infectionJournal of Hospital Infection, 2012
- Prospective Observational Study Comparing Three Different Treatment Regimes in Patients with Clostridium difficile InfectionAntimicrobial Agents and Chemotherapy, 2012
- Genetic markers for Clostridium difficile lineages linked to hypervirulenceMicrobiology, 2011
- Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infectionJournal of Antimicrobial Chemotherapy, 2011
- Thirty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008Journal of Hospital Infection, 2011
- Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin ProductionJournal of Bacteriology, 2010
- Complete Restriction of Fluoroquinolone Use to Control an Outbreak ofClostridium difficileInfection at a Community HospitalInfection Control & Hospital Epidemiology, 2009
- Toxin B is essential for virulence of Clostridium difficileNature, 2009
- Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic reviewJournal of Antimicrobial Chemotherapy, 2003
- Clostridium difficile–Associated DiarrheaClinical Infectious Diseases, 1998